Stockscreener 앱 받기
31.22
2.59%
-0.83
Beam Therapeutics Inc 주식(BEAM)의 최신 뉴스
Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 6.1%Should You Sell? - MarketBeat
Earnings Report: Is Beam Therapeutics Inc a cyclical or defensive stock2025 EndofYear Setup & Accurate Intraday Trade Tips - baoquankhu1.vn
Aug Intraday: What is Rapid7 Incs 5 year growth outlookPortfolio Return Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Beam Therapeutics stock maintains Buy rating at H.C. Wainwright on FDA alignment - Investing.com
Gene editing trials in sickle cell advance as Beam builds $1.1B cash - Stock Titan
Institution Moves: Will BHRPRD announce a stock splitPortfolio Risk Report & Weekly Return Optimization Plans - baoquankhu1.vn
Bernstein Keeps Their Buy Rating on Beam Therapeutics (BEAM) - The Globe and Mail
Sumitomo Mitsui Trust Group Inc. Has $117.24 Million Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
BEAM: Base editing programs advance toward approval, backed by strong data, funding, and scalable technology - TradingView — Track All Markets
BEAM: Predictable gene editing advances drive pivotal programs and commercial readiness into 2029 - TradingView — Track All Markets
Buyback Watch: How does AHTPRI score in quality rankingsQuarterly Market Summary & Growth Focused Entry Point Reports - baoquankhu1.vn
BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises - sharewise.com
Beam Therapeutics: Pivoting From Platform To Execution Stage (NASDAQ:BEAM) - Seeking Alpha
April 17th Options Now Available For Beam Therapeutics - Nasdaq
Beam Therapeutics (BEAM) to Submit Biologics License Application for Risto-cel by End of 2026 - Intellectia AI
Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029 - Yahoo Finance
Beam Therapeutics stock today: BEAM edges lower premarket after FDA alignment sparks 22% rally - TechStock²
Beam Therapeutics Price Target Upgrade Signals Positive Outlook - timothysykes.com
Gene Editor Soars To 10-Month High On Bullish FDA News - Investor's Business Daily
Beam Therapeutics (NASDAQ:BEAM) Shares Gap UpTime to Buy? - MarketBeat
Beam Therapeutics stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Nigeria
Key facts: Beam Therapeutics seeks FDA approval for BEAM-302 therapy - TradingView — Track All Markets
Beam Therapeutics Stock Surges: What's Driving The Sudden Jump? - Benzinga
Beam Therapeutics (BEAM) Shares Surge Nearly 28% - GuruFocus
Beam Therapeutics stock maintains Overweight rating at Cantor Fitzgerald - Investing.com
BEAM Stock In Focus As FDA Alignment Wins William Blair’s Praise - Stocktwits
Beam Therapeutics Advances Genetic, Hematology Pipeline, Extends Cash Runway to 2029; Shares Rise - marketscreener.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Beam Therapeutics (BEAM) Sees Positive Developments in Regulator - GuruFocus
Beam Therapeutics higher after reaching FDA alignment on BEAM-302 - TipRanks
Beam Therapeutics (BEAM) Eyes Accelerated FDA Approval for BEAM-302 - GuruFocus
Beam Therapeutics (BEAM) Shares Soar on Strategic Advances - GuruFocus
Beam Therapeutics (BEAM) Shares Surge Over 23% in Recent Trading - GuruFocus
Bernstein raises Beam Therapeutics stock price target to $37 on AATD program outlook - Investing.com Australia
Why Beam Therapeutics Stock Is Sliding Despite Progress - TipRanks
Beam Therapeutics outlines 2026 strategy and extends runway - TipRanks
Beam Therapeutics To Report BEAM-302 Trial Data In Q1; Submit Risto-cel BLA By Year-End 2026 - Nasdaq
Beam Therapeutics sets strategic priorities for its genetic disease & hematology franchises - marketscreener.com
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition - The Manila Times
Beam Therapeutics (NASDAQ:BEAM) Cut to "Sell" at Wall Street Zen - MarketBeat
Aug Analyst Calls: Will Beam Therapeutics Inc. stock benefit from infrastructure spendingTreasury Yields & Free Community Supported Trade Ideas - ulpravda.ru
Will Beam Therapeutics Inc. stock reach all time highs in 2025Treasury Yields & Proven Capital Preservation Methods - Улправда
Behavioral Patterns of BEAM and Institutional Flows - Stock Traders Daily
Beam Therapeutics (NASDAQ:BEAM) Upgraded to "Hold" at UBS Group - MarketBeat
What catalysts could drive Beam Therapeutics Inc. stock higherGap Down & Real-Time Buy Zone Alerts - ulpravda.ru
Will Beam Therapeutics Inc. stock beat EPS estimatesMarket Risk Summary & Weekly Watchlist for Consistent Profits - ulpravda.ru
What dividend safety score for Beam Therapeutics Inc. stock2025 EndofYear Setup & Daily Technical Stock Forecast Reports - ulpravda.ru
How resilient is Beam Therapeutics Inc. stock in market downturnsWatch List & Low Drawdown Momentum Ideas - ulpravda.ru
Gene Editing Tools Market to Reach US$ 1,700.05 million by 2033 | - openPR.com
Bank of America Securities Reaffirms Their Buy Rating on Beam Therapeutics (BEAM) - The Globe and Mail
Does ARK’s BEAM (BEAM) Buying and Regulatory Momentum Reinforce the Bull Case for Base Editing? - simplywall.st
UBS Initiates Coverage of Beam Therapeutics (BEAM) with Neutral Recommendation - Nasdaq
Is Beam Therapeutics Inc. stock a defensive play in 2025Resistance Zone Identification & Free High Profit Capital Plays - ulpravda.ru
UBS Initiates Coverage on Beam Therapeutics (BEAM) with Neutral - GuruFocus
UBS Initiates Beam Therapeutics at Neutral With $28 Price Target - MarketScreener
Beam upgraded to Buy at BofA Securities on recent genetic condition treatment - MSN
Beam Therapeutics stock initiated with Neutral rating by UBS - Investing.com South Africa
4.73%
0.92%
자본화:
|
볼륨(24시간):